ROTH Capital Partners Acts as Joint Book-Running Manager
for Tonix Pharmaceuticals Holding Corp. (TNXP) in its
$31.1 Million Follow-On

For more information please contact:

Investment Banking
John Chambers
Vice-Chairman and
Head of Healthcare Investment Banking
(646) 358-1901
jchambers@roth.com

Michael Margolis, R.Ph.
Managing Director
(646) 358-1902
mmargolis@roth.com

Warren Dunnavant II
Senior Vice President
(646) 358-1903
wdunnavant@roth.com

Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703

agurewitz@roth.com

Nazan Akdeniz
Senior Vice President
(949) 720-5740

nakdeniz@roth.com

Lou Ellis
Senior Vice President
(949) 720-5739

lellis@roth.com

Transaction Information

On February 9th, Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) closed an underwritten public offering of its common stock. Including the partial exercise of the over-allotment option, the Company sold an aggregate of 5,318,700 shares of its common stock. The shares were sold at the public offering price of $5.85 per share, bringing the aggregate gross proceeds from the offering to approximately $31.1 million.

 

ROTH Capital Partners acted as joint book-running manager for the offering.

 

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage company developing first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache (ETTH). These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix's lead candidate, TNX-102 SL, is intended to be a first-line treatment for fibromyalgia and for PTSD. A Phase 2b trial of TNX-102 SL in fibromyalgia (BESTFIT) has been completed, and Tonix will initiate a Phase 3 program in the second quarter of 2015 to support product registration in the U.S. A Phase 2 trial of TNX-102 SL in PTSD (AtEase) commenced in the first quarter of 2015. A Phase 2 trial of TNX-201 for ETTH will begin in the second quarter of 2015. To learn more, please visit www.tonixpharma.com. (Source: Company Press Release 2/9/15)

 

About ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. and Hong Kong. For more information on ROTH, please visit www.roth.com

 

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2015.